Discipline of Natural Sciences, Indian Institute of Information Technology, Design, and Manufacturing, Dumna Airport Road, Khamaria, Jabalpur-482005, India.
Phys Chem Chem Phys. 2020 Dec 23;22(48):28115-28122. doi: 10.1039/d0cp05297c.
Repurposed drugs are now considered as attractive therapeutics against COVID-19. It is shown that Remdesivir, a nucleoside drug that was originally invented for the Ebola virus, is effective in suppressing the replication of SARS-CoV-2 that causes COVID-19. Similarly, Galidesivir, Favipiravir, Ribavirin, N4-hydroxycytidine (EIDD-1931), and EIDD-2801 (a prodrug of EIDD-1931) were also found to be effective against COVID-19. However, the mechanisms of action of these drugs are not yet fully understood. For example, in some experimental studies, these drugs were proposed to act as a RNA-chain terminator, while in other studies, these were proposed to induce base-pair mutations above the error catastrophe limit to stall the replication of the viral RNA. To understand the mutagenic effects of these drugs, the role of different tautomers in their base-pairing abilities is studied here in detail by employing a reliable dispersion-corrected density functional theoretic method. It is found that Remdesivir and Galidesivir can adopt both amino and imino tautomeric conformations to base-pair with RNA bases. While the insertions of G and U are preferred against the amino tautomers of these drugs, the insertion of C is mainly possible against the imino tautomers. However, although Favipiravir and Ribavirin can make stable base pair interactions by using their keto and enol tautomers, the formation of the latter pairs would be less probable due to the endothermic nature of the products. Interestingly, the insertions of all of the RNA bases are found to be possible against the keto tautomer of Favipiravir, while the keto tautomer of Ribavirin has a clear preference for G. Remarkably, due to the negligible difference in the stability of EIDD-2801 and EIDD-1931, these tautomers would coexist in the biological environment. The insertion of G is found to be preferred against EIDD-1931 and the incorporations of U, A, and G are preferred opposite EIDD-2801. These findings suggest that base-pair mutations are the main causes of the antiviral properties of these drugs.
重新利用的药物现在被认为是治疗 COVID-19 的有吸引力的疗法。已表明,最初为埃博拉病毒发明的核苷药物瑞德西韦可有效抑制导致 COVID-19 的 SARS-CoV-2 的复制。同样,加地昔韦、法匹拉韦、利巴韦林、N4-羟基胞苷(EIDD-1931)和 EIDD-2801(EIDD-1931 的前药)也被发现对 COVID-19 有效。然而,这些药物的作用机制尚未完全了解。例如,在一些实验研究中,这些药物被提议作为 RNA 链终止子,而在其他研究中,这些药物被提议诱导碱基对突变超过错误灾难极限以阻止病毒 RNA 的复制。为了了解这些药物的诱变作用,这里通过使用可靠的色散校正密度泛函理论方法详细研究了不同互变异构体在它们与 RNA 碱基配对能力中的作用。结果发现,瑞德西韦和加地昔韦可以采用氨基和亚氨基互变异构体与 RNA 碱基配对。虽然 G 和 U 的插入更倾向于这些药物的氨基互变异构体,但 C 的插入主要可能与亚氨基互变异构体有关。然而,尽管法匹拉韦和利巴韦林可以通过使用其酮和烯醇互变异构体形成稳定的碱基对相互作用,但由于产物的吸热性质,后一种配对的形成不太可能。有趣的是,发现所有 RNA 碱基的插入都可能针对法匹拉韦的酮互变异构体,而利巴韦林的酮互变异构体对 G 有明显的偏好。值得注意的是,由于 EIDD-2801 和 EIDD-1931 的稳定性差异可以忽略不计,这些互变异构体将在生物环境中共存。发现 G 的插入优先于 EIDD-1931,而 U、A 和 G 的掺入优先于 EIDD-2801。这些发现表明碱基对突变是这些药物抗病毒特性的主要原因。